Bosch and Klenzaids Plan Joint Venture in India
Processing and packaging specialist Bosch Packaging Technology and Klenzaids Contamination Controls are planning a joint venture in India. Both companies signed agreements to this effect on 28 November 2014. The plan is for Bosch to acquire a 49% share in Klenzaids, an owner-managed company that produces processing, packaging, and clean-room technology for the global pharmaceutical industry. By setting up the joint venture, the two partners aim to extend their global reach, particularly in liquid pharmaceuticals and packaging machines for clean-room environments.
The Klenzaids and Bosch Packaging Technology product portfolios complement each other across the board. In particular, the joint venture will allow the companies to better satisfy Indian customers’ growing demand for complete lines from a single source. Based in Mumbai, Klenzaids generated sales of around €6 million in 2013 and employs some 350 people. Bosch Packaging Technology, which last year achieved global sales of €1.1 billion and employs some 5600 associates worldwide, already has a presence in India through its Verna location in the state of Goa. The joint venture is set to be headquartered in Mumbai and is expected to employ some 380 associates. The plan is subject to the approval of the antitrust authorities. The purchase price for the shares acquired by Bosch was not disclosed.
Better products and services for customers in India
The joint venture is being set up primarily to benefit Indian customers. Klenzaids will contribute its expertise in clean-room and processing technologies as well as peripheral systems, and Bosch will contribute its strength in innovative filling technologies. Klenzaids provides customers in the private and public sectors not just with plants, systems, and accessories but also with turnkey solutions: buildings and equipment that a customer can use as soon as they are built or assembled to process and package its particular product. These solutions include laboratories with the highest protection class for use in the field of biosafety.
Profitable growth and value orientation
Friedbert Klefenz, president of Bosch Packaging Technology, said: “We already have a long history of trusted collaboration with Klenzaids. The company is known for employing excellent people and for providing high-quality products and services. I am delighted at the prospect of a future together.” Hamish Shahani, managing director of Klenzaids, said: “Joining forces and pooling our resources will give us a stronger starting position in the emerging Indian market. Despite our different regional backgrounds, Bosch and Klenzaids have a lot in common. Both place great emphasis on profitable growth, innovative strength, reliability, a motivated workforce, and strong value orientation.”
Complete lines from a single source
Klenzaids is an Indian family-run business with a product portfolio that includes laboratory and transfer systems designed to meet clean-room requirements. These machines are indispensable for the sterile production of liquid pharmaceuticals. One of the company’s USPs is its ability to supply laboratories that meet biological safety class standards 2–4. Class 4 laboratories have to satisfy the highest safety requirements, such as being able to guarantee the absolute isolation of microorganisms from the environment. Among the company’s other strengths are isolators and processing technologies for the production of liquid pharmaceuticals.
Strategically important complement to Bosch’s Goa location
Bosch Packaging Technology has been developing, building, and selling vertical and horizontal flow wrapping machines for packaging food, as well as filling and sealing machines for liquid pharmaceuticals at its location in Verna since 2012. To date, Bosch Packaging Technology has sold more than 1500 packaging machines to leading brand companies in the food and pharmaceutical industries.
Commenting on the agreement, Dr Steffen Berns, president of Bosch India, said: “Following the inauguration of our manufacturing unit in Verna, this is the second milestone for our packaging technology business in two years. I am extremely confident that this new partnership will further strengthen our product portfolio and market reach. The activities of both parent companies dovetail perfectly, and our pharmaceuticals unit as well as our customers will benefit immensely from this joint venture.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance